Acorda Therapeutics
ACOR
ACOR was delisted on the 11th of April, 2024.
175 hedge funds and large institutions have $1.42B invested in Acorda Therapeutics in 2018 Q2 according to their latest regulatory filings, with 28 funds opening new positions, 61 increasing their positions, 53 reducing their positions, and 15 closing their positions.
87% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 15
17% more capital invested
Capital invested by funds: $1.22B → $1.42B (+$207M)
15% more repeat investments, than reductions
Existing positions increased: 61 | Existing positions reduced: 53
8% more funds holding
Funds holding: 162 → 175 (+13)
34% less call options, than puts
Call options by funds: $18.7M | Put options by funds: $28.5M
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
+$27.2M |
| 2 |
Renaissance Technologies
New York
|
+$12.1M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$11.5M |
| 4 |
BlackRock
New York
|
+$10.3M |
| 5 |
D.E. Shaw & Co
New York
|
+$4.99M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HEC
Hudson Executive Capital
New York
|
-$31.1M |
| 2 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$30.5M |
| 3 |
SCM
Scopia Capital Management
New York
|
-$21.4M |
| 4 |
HM
HealthCor Management
New York
|
-$18.2M |
| 5 |
State Street
Boston,
Massachusetts
|
-$16.2M |
ACOR Hedge Fund Activity: Q2 2018 in Review
175 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Acorda Therapeutics (ACOR) for Q2 2018, worth a combined $1.42B — up 17% from $1.22B a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new ACOR positions and 15 closed out — a net gain of 13 holders — while 61 added to existing stakes and 53 trimmed.
The largest buyer was Invesco, adding an estimated $27.2M. The largest seller was Hudson Executive Capital, exiting entirely with an estimated $31.1M sold.
- 175 institutional investors held Acorda Therapeutics (ACOR) as of Q2 2018, up from 162 in Q1 2018.
- Funds reported $1.42B of Acorda Therapeutics stock for Q2 2018, up 17% quarter-over-quarter.
- 28 funds opened new Acorda Therapeutics positions in Q2 2018 and 15 closed out, a net change of +13 holders.
- The largest Acorda Therapeutics buyer in Q2 2018 was Invesco, an estimated $27.2M added.
- The largest Acorda Therapeutics seller in Q2 2018 was Hudson Executive Capital, an estimated $31.1M sold.
Based on aggregated 13F filings for Q2 2018.